Company Profile

New You, Inc., through its wholly owned subsidiary, New You LLC, markets and sells its products through a multi-level marketing and direct sales opportunity to independent business owners called 'Brand Partners.' The Company is engaged in marketing cannabidiol (CBD) products, which include CBD beverage enhancers that can be added to any beverage, CBD infused coffee, and CBD oil tinctures. Its product consists of Primus Skin Care and Infinite. Primus Skin Care develops products designed to combine anti-inflammatory benefits of CBD with different skin-enhancing properties of existing ingredients, such as hyaluronic acid, marshmallow root, immortelle oil. Infinite is a CBD manufacturer of isolate-based products, such as oils, gummies, capsules, creams and men's self-care products differentiated by its use of nanoparticles to improve products performance. It also produces and sells bulk nano products for use by third parties. It is also developing a synthetic CBD-based sugar alternative.

Employees

Sector

Pharmaceuticals

More about the company

16/06/25	REIC Holdings, Inc. cancelled the transaction announced on June 17, 2024	CI
11/08/24	REIC Holdings, Inc. announced that it expects to receive $20 million in funding	CI
02/07/24	REIC Holdings, Inc. announced that it expects to receive $20 million in funding	CI
16/06/24	New You, Inc. announced a financing transaction	CI
08/10/21	Jason Frankovich Resigns from Position as Executive Chairman and as A Member of New You Inc. Board of Directors	CI
17/09/21	New You Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
17/06/21	New You Inc. Appoints John Driscoll as Chief Financial Officer	CI
17/06/21	New You, Inc. Appoints John Driscoll as Member of Board of Directors	CI
24/05/21	New You Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
12/05/21	New You Inc. Appoints Jason Frankovich as Executive Chairman	CI
06/05/21	New You Inc. acquired ST Brands, Inc.	CI
08/04/21	New You Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
08/12/20	New You Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI

07/12/22	Author Dr. Rhonda Smith, ND, BCALP’s New Book, "Divine Core Transformation," is Aimed at Helping Readers Rethink & Heal from Their Addictive Relationships & Trauma	AQ
08/10/21	NEW YOU, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
22/09/21	NEW YOU : Financial Statements and Exhibits (form 8-K/A)	AQ
20/09/21	NEW YOU : 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	AQ
17/09/21	NEW YOU : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Manager	Title	Age	Since
Raymond W. Grimm CEO	Chief Executive Officer	80	10/07/2018
Greg Montoya PSD	President	62	-
James Patrick Sinkes DFI	Director of Finance/CFO	41	-

Director	Title	Age	Since
Nish Mehta BRD	Director/Board Member	59	10/07/2018
Raymond W. Grimm CHM	Chairman	80	10/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
05/02/20	James Patrick Sinkes	Other	Controller/Auditor	110,000	0.3335%
05/02/20	Jared Berry	Other		10,641,107	32.2602%
05/02/20	Gregory Lee Montoya	Other	Chairperson	1,080,000	3.2742%

New You, Inc. Share Price

Stocks

NWYU

US6501491079

Pharmaceuticals

Latest news: New You, Inc.

Press Releases: New You, Inc.

Managers and Directors: New You, Inc.

Latest insider transactions

Pharmaceuticals Wholesale

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEW YOU, INC.	-.--%	-.--%	-	-	16.68K
ELI LILLY AND COMPANY	-0.39%	+10.46%	+57.60%	+143.48%	1,263B
JOHNSON & JOHNSON	-1.54%	+1.10%	+44.54%	+79.19%	658B
ABBVIE INC.	-2.26%	+0.68%	+36.20%	+101.52%	521B
ROCHE HOLDING AG	-1.54%	+0.18%	+53.06%	+66.79%	391B
MERCK & CO., INC.	-0.60%	+5.68%	+80.14%	+44.48%	369B
NOVARTIS AG	-1.69%	+3.17%	+32.18%	+55.35%	307B
ASTRAZENECA PLC	-0.72%	+7.83%	+12.10%	+33.76%	290B
AMGEN INC.	+0.05%	+4.90%	+57.41%	+74.96%	252B
GILEAD SCIENCES, INC.	-0.16%	+7.03%	+39.16%	+109.09%	212B
Average	-0.91%	+5.90%	+45.82%	+78.73%	473.55B
Weighted average by Cap.	-1.02%	+6.60%	+48.65%	+93.25%